All articles tagged with #car t therapy
Sam Neill says he is cancer-free after chemotherapy stopped working, thanks to CAR-T cell therapy, and he’s advocating for government funding of the treatment in Australia with support from the Snowdome Foundation.
Sam Neill, the Emmy-nominated star of Jurassic Park, said he’d been living with a type of lymphoma for about five years after chemotherapy stopped working, but after receiving CAR-T-cell therapy he is now cancer-free, per 7NEWS.
Sam Neill says he is cancer-free after undergoing CAR-T-cell therapy following chemotherapy’s failure, marking a five-year battle with angioimmunoblastic T-cell lymphoma. A recent scan found no cancer, and he plans to return to acting while advocating for broader CAR-T access in Australia.
A 47-year-old German woman with refractory autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid syndrome was treated with CAR-T cell therapy to eradicate rogue B cells and reboot her immune system. After exhausting standard therapies, this radical approach led to dramatic improvement and is described by doctors as a landmark in immunotherapy.
A 47-year-old woman with three autoimmune diseases caused by B-cell antibodies—autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid syndrome—was treated with a single dose of engineered CAR-T cells after failing multiple therapies. Following targeted conditioning chemotherapy, her blood counts normalized within a month, and 14 months later she remains symptom-free and off all medications, suggesting CAR-T therapy could offer a one-off cure for some autoimmune conditions, though this is a single case and long-term safety and applicability need further study.
Washington University researchers used CAR-T cell therapy to reprogram brain immune cells to recognize and clear amyloid beta plaques in mice, reducing plaques and dampening neuroinflammation. This is the first application of CAR-T to a neurodegenerative disease, but it is early-stage and not yet ready for humans; scientists plan safety and dosing studies and will explore translation to other disorders, with potential relevance for veterans at risk of dementia.
U.S. researchers are testing CAR-T therapy—reprogramming a patient’s own T cells to attack overactive B cells implicated in MS—to see if it can reach the brain and slow progression. Early, small trials (including four MS patients at the Cleveland Clinic) show uncertain outcomes and potential risks like cytokine release syndrome and neurotoxicity, with experts cautioning that this approach is highly experimental and may not be more effective than existing MS drugs. Still, findings could improve understanding of MS and guide future therapies, even if not curative.
Researchers engineered astrocytes to express a CAR targeting amyloid beta, turning them into brain “super cleaners.” In mice, a single gene-therapy injection either prevented plaque formation when given early or reduced existing amyloid plaques by ~50%, signaling a potential new immunotherapy approach for Alzheimer's—though safety and human trials remain to be established.
A CART4-34 CAR-T therapy targets the IGHV4-34 gene in B-cell cancer, destroying lymphoma cells in mice as effectively as CD19 CAR-T while sparing healthy B cells and avoiding immune suppression; the approach could also be used to treat autoimmune conditions such as lupus, but human trials are needed.
Bristol Myers Squibb is acquiring Orbital Therapeutics for $1.5 billion to expand into in vivo CAR-T cell therapies, focusing on autoimmune diseases and leveraging Orbital's RNA-based approach to produce CAR-T cells within the body, marking a significant move in the biotech and cell therapy markets.
Sharon Smith, a healthy mother of two from Liverpool, was unexpectedly diagnosed with acute lymphoblastic leukemia after experiencing sudden chest pain, despite having no prior symptoms. She underwent chemotherapy, a stem cell transplant, and innovative CAR-T therapy, which ultimately proved successful, offering her hope for the future.
Johnson & Johnson's early-stage clinical trial of a dual-targeting CAR-T therapy for lymphoma shows promising results, with a 100% response rate in patients with prior treatment, and manageable safety profile, marking a significant step forward in blood cancer treatment.
A study shows that a single infusion of CAR-T therapy cilta-cel can lead to at least five years of remission in about one-third of patients with relapsed or refractory multiple myeloma, suggesting potential curative outcomes for some patients.
A new study published in Nature reveals promising results for CAR-T therapy in treating diffuse intrinsic pontine gliomas (DIPG), a highly aggressive childhood brain tumor. Led by Michelle Monje-Deisseroth at Stanford University, the trial showed that four out of eleven patients experienced significant tumor reduction, with one patient remaining in complete remission 30 months post-treatment. Despite the high mortality rate, these findings offer hope for a condition previously deemed untreatable.
Sierra Butler, a West Virginia teacher diagnosed with lupus, is participating in a groundbreaking clinical trial at the Cleveland Clinic using CAR-T therapy, which genetically modifies a patient's white blood cells to attack problematic cells. This therapy, commonly used for cancer, has shown promising results in treating lupus, potentially leading to remission. Butler's condition has significantly improved, and the trial offers hope for a long-term solution to her treatment-resistant lupus.